Cannabis Law Report
DECEMBER 9, 2021
The Financing will allow the Company to continue progressing its R&D, clinical trials and technology initiatives. “I I’m proud of our accomplishments to date and look forward to kicking off multiple clinical trials in early 2022,” said CEO, Josh Bartch. DENVER, Dec. Matthew Johnson.
Cannabis Law Report
MARCH 12, 2020
They write… The Psychedelics as Medicine Report presents unparalleled insights and intelligence into this emerging movement, helping to guide investors, operators and regulators through this transient phase. Download your free copy now. Unsurprisingly the event follows in June.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Cannabis Law Report
NOVEMBER 24, 2019
Cannabis-based medicinal products. Making decisions using NICE guidelines explains how we use words to show the strength (or certainty) of our recommendations, and has information about prescribing medicines (including off-label use), professional guidelines, standards and laws (including on consent and mental capacity), and safeguarding.
Project CBD
FEBRUARY 28, 2023
The following excerpt analyzes CBD marketing trends reported by the American Botanical Council, a membership organization that educates consumers, health care professionals, journalists, and others about the safe and effective use of medicinal plants. Available at: www.fda.gov/media/131878/download. Accessed October 17, 2022.
Cannabis Law Report
JULY 15, 2022
The first Australian company to be licensed to cultivate and manufacture medicinal marijuana has praised the Federal Government’s plan to allow exports of cannabis-based medicines. “It’s very important from our perspective to ensure that the Australian patient gets medicine first. The ABC reported back in 2018.
TheAnswerPage
JANUARY 11, 2022
As reviewed in a recent Forbes article, “a study of more than 400 health care professionals has revealed that most physicians lack knowledge of medicinal cannabis, with 65% saying that they have been asked about medical marijuana as a treatment for chronic pain but were unable to answer their patients’ questions” (1). Nov 24 2021.
CannaMD
MARCH 8, 2020
Few randomized clinical trials have been conducted or are planned to explore the effects of marijuana on cardiovascular risk. Screening and testing for use of marijuana are encouraged in clinical settings, especially in the care of young patients presenting with cardiovascular disease. More research is needed.
Expert insights. Personalized for you.
52 
Let's personalize your content